#

+1 (917) 893 7512

  • #
  • #
  • #
#

The US Onychomycosis Market: Size, Trends and Forecasts (2018 Edition)

Publish Date:Sep 2018
No. of Pages:61

Format : Adobe Reader (PDF) Instant delivery

US$ 800.00

Scope of the Report

The report entitled “The US Onychomycosis Market (2018 Edition)”, provides analysis of the US onychomycosis market, with detailed analysis of market size and growth, market share and economic impact of the industry. The analysis includes the market by value, by volume and by segments. The report also includes the detailed analysis of the segments of the onychomycosis market, comprising of market by value, by volume and by average prices.

In addition to this, a global analysis of the overall skin infections drugs market in terms of value followed by analysis of drugs used for the treatment of onychomycosis type of skin infection such as Kerydin and Jublia in terms of value has been done in this report.

Valeant Pharmaceuticals, Pfizer, Inc., Novartis AG and Johnson & Johnson are some of the key players operating in the US onychomycosis market, whose company profiling has been done in the report. In this segment of the report, business overview, financial overview and business strategies of the companies are provided.

Company Coverage

Valeant Pharmaceuticals
Pfizer Inc.
Novartis AG
Johnson & Johnson

Executive Summary

Onychomycosis is a condition of fungal nail infection. Onychomycosis begins in the nail bed and progresses to the nail plate, causing the nail to become discolored, deformed, and even separated from the nail bed. Onychomycosis has a significant chance of reoccurrence. Of all the nail abnormalities in the world, around 50% are the case of onychomycosis. In most of the cases it occurs in the toenails. Onychomycosis is not a life threatening disease but, may persist or worsen if not treated.

Symptoms of onychomycosis are changes in appearance of the nail, interference with standing, walking, and exercising, pain, discomfort, etc. The causative pathogens of onychomycosis include dermatophytes (most common), Candida, and nondermatophytic molds.

There are five types of Onychomycosis: Distal Subungual Onychomycosis, White superficial onychomycosis, Proximal subungual onychomycosis, Endonyx onychomycosis and Candidal onychomycosis. Two types of treatments are available of onychomycosis: Oral Treatment and Topical Treatment. Oral treatment includes: Terbinafine, Itraconazole, etc. and topical treatment includes Kerydin, Jublia, etc. Nonpharmacologic approaches are also there, which includes the following: Laser treatment, Photodynamic therapy, etc.

The US onychomycosis market (prescription drugs) has increased with a healthy growth rate over the years and is expected to increase further during the forecasted period. The US onychomycosis market is supported by various growth drivers, such as rising per capita healthcare expenditure, increasing diabetic patients, ageing population, introduction of new drugs, etc. Yet, the market faces certain challenges, such as, reimbursements, low awareness, side effects, etc.

1. Executive Summary

2. Introduction

2.1 Onychomycosis: An Overview
2.1.1 Signs and Symptoms
2.1.2 Causes of Onychomycosis

2.2 Types of Onychomycosis
2.3 Treatment For Onychomycosis

3. Global Market Analysis 

3.1 Global Skin Infections Drugs Market: An Analysis
3.1.1 Global Skin Infections Drugs Market by Value 
3.1.2 Global Skin Infections Drugs Market by Products (Drugs for Onychomycosis and Other Skin Infection Drugs)

3.2 Global Onychomycosis Market: Product Analysis 
3.2.1 Global Kerydin Drugs Market by Value
3.2.2 Global Jublia Drugs Market by Value 

3.3 Global Onychomycosis Market: Pipeline Drugs Analysis
3.3.1 Global Skin Infection Market- Phase II Drugs (Onychomycosis) Pipeline Forecast
3.3.2 Global Skin Infection Market- Phase III Drugs (Onychomycosis) Pipeline Forecast

3.4 Onychomycosis Market: New Drugs Overview

4. US Market Analysis

4.1 The US Nail Care Market: An Analysis

4.1.1 The US Nail Care Market by Value
4.1.2 The US Nail Care Market by Segments (Jublia and Other Generic Drugs Including Kerydin)

4.2  The US Nail Care Market: Segment Analysis

4.2.1 The US Jublia Drug Market by Value
4.2.2 The US Jublia Drug Market by Volume
4.2.3 The US Kerydin Drug Market by Value
4.2.4 The US Kerydin Drug Market by Volume
4.2.5 The US Generic Drugs Market by Value

4.3 The US Onychomycosis Market: An Analysis

4.3.1 The US Onychomycosis Market by Prevalence 
4.3.2 The US Onychomycosis Market Prevalence by Segments

5. Competitive Landscape

5.1 Competition in Onychomycosis Prescription Market: An Overview
5.2 Financial Comparison of Major Players of the US Onychomycosis Market 

6. Company Profiles 

6.1 Valeant Pharmaceuticals
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategy

6.2 Pfizer
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategy

6.3 Johnson & Johnson
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategy

6.4 Novartis AG
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategy
Figure 1: Types of Onychomycosis
Figure 2: Treatment for Onychomycosis
Figure 3: Global Skin Infection Drugs Market; 2017-2026 (US$ Billion)
Figure 4: Global Skin Infections Drugs Market by Products; 2017 (Percentage,%)
Figure 5: Global Kerydin Drugs Market by Value; 2017-2026 (US$ Million)
Figure 6: Global Jublia Drugs Market by Value; 2017-2026 (US$ Million)
Figure 7: Phase II Drugs (Onychomycosis) Pipeline Forecast; 2021-2026 (US$ Million)
Figure 8: Phase III Drugs (Onychomycosis) Pipeline Forecast; 2018-2026 (US$ Million)
Figure 9: The US Nail Care Market by Value; Jun16–Apr17 (US$ Million)
Figure 10: The US Nail Care Market by Segments; 1Q2017
Figure 11: The US Jublia Drug Market by Value; 3Q2016-3Q2017 (US$ Million)
Figure 12: The US Jublia Drug Market by Volume; 4Q2014-1Q2016 (Count)
Figure 13: The US Kerydin Drug Market by Value; 2Q2015-1Q2016 (US$ Million)
Figure 14: The US Kerydin Drug Market by Volume; 4Q2014-1Q2016 (Count)
Figure 15: The US Generic Drugs Market by Value; 2012-2017 (US$ Million)
Figure 16: The US Onychomycosis Market by Prevalence; 2016 (Million)
Figure 17: The US Onychomycosis Market Prevalence by Segments; 2015
Figure 18: Valeant Revenue; 2013-2017 (US$ Billion)
Figure 19: Valeant Revenue by Segments; 2017 (Percentage, %)
Figure 20: Pfizer Revenue; 2013-2017 (US$ Billion)
Figure 21: Pfizer Revenue by Segments; 2017 (Percentage, %)
Figure 22: Johnson Sales; 2013-2017 (US$ Billion)
Figure 23: Johnson Sales by Business Segments; 2017 (Percentage, %)
Figure 24: Johnson Sales by Region; 2017 (Percentage, %)
Figure 25: Novartis Net Sales; 2013-2017 (US$ Billion)
Figure 26: Novartis Sales by Segment; 2017 (Percentage, %)
Figure 27 : Novartis Sales by Region; 2017 (Percentage, %)
Table 1: Treatments Available for Onychomycosis
Table 2: Financial Comparison of Major Players of the US Onychomycosis Market